Sign in
CompletedNo phase

FlowTriever2 Pulmonary Embolectomy Clinical Study

Key facts

Who runs it
Inari Medical
Where
Camden, Knoxville, Louisville, New Haven, Savannah, Tucson, and Tulsa, United StatesSee the 7 sites
Trial code
Status
Completed
People taking part
50 people enrolled
Started
14 Feb 2023
Ended
9 Sept 2024
Type of study
Interventional
Treatments tested
  • FlowTriever2 Catheter
Record updated
8 October 2025

Who can take part

Age
18 years to 75 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 33 criteriaShow less

Who can take part

  • Clinical signs and symptoms consistent with acute PE
  • PE symptom duration ≤ 14 days
  • CTA evidence of proximal PE (filling defect in at least one main or lobar pulmonary artery)
  • RV/LV ratio of ≥ 0.9 (NOTE: Enrollment qualification assessment based on Investigator's interpretation of RV/LV ratio)
  • Systolic blood pressure ≥ 90 mmHg (initial SBP may be ≥ 80 mmHg if the pressure recovers to ≥ 90 mmHg with fluids)
  • Stable heart rate < 130 BPM prior to procedure
  • Patient is deemed medically eligible for interventional procedure(s), per institutional guidelines and/or clinical judgment
  • FlowTriever2 Catheter enters the vasculature

Who cannot take part

  • Cardiovascular or pulmonary surgery within last 7 days
  • Known anaphylactic reaction to radiographic contrast agents that cannot be pretreated
  • Current participation in another investigational drug or device treatment study
  • Pulmonary hypertension with peak pulmonary artery pressure > 70 mmHg by right heart catheterization
  • Actively progressing cancer
  • Known bleeding diathesis or coagulation disorder
  • History of severe or chronic pulmonary arterial hypertension
  • History of uncompensated heart failure
  • History of underlying lung disease that is oxygen dependent
  • History of chest irradiation
  • History of heparin-induced thrombocytopenia (HIT) Any contraindication to systemic or therapeutic doses heparin or anticoagulants
  • Platelets < 100,000/μL
  • Serum creatinine > 1.8 mg/dL
  • INR > 3
  • History of chronic left heart disease with left ventricular ejection fraction ≤ 30%
  • Thrombolytic use within 30 days of baseline CTA
  • Vasopressor requirement after fluids to keep pressure ≥ 90 mmHg
  • FiO2 requirement > 40% or > 6 LPM to keep oxygen saturation > 90%
  • Hematocrit < 28% (NOTE: hematocrit required within 6 hours of index procedure)
  • Major trauma Injury Severity Score (ISS) > 15
  • Presence of intracardiac lead in the right ventricle or right atrium placed within 6 months
  • Left bundle branch block
  • Imaging evidence or other evidence that suggests, in the opinion of the Investigator, the Subject is not appropriate for mechanical thrombectomy intervention (e.g., inability to navigate to target location, predominately chronic clot, or non-clot embolus)
  • Life expectancy of < 90 days, as determined by Investigator
  • Female who is pregnant or nursing

Where in United States

  • Virtua HealthCamden, United States
  • University of Tennessee Medical CenterKnoxville, United States
  • Baptist HealthLouisville, United States
  • Yale UniversityNew Haven, United States
  • Memorial Health University Medical CenterSavannah, United States
  • Carondelet St. Joseph's HospitalTucson, United States
  • Oklahoma Heart InstituteTulsa, United States

About the trial

What the trial wants to find out

The FLARE-FT2 confirmatory study is a prospective, single-arm, multicenter study of the FlowTriever2 Catheter for mechanical thrombectomy of pulmonary embolism (PE).

The group in the trial

  • All SubjectsTreatment being tested

    All participants who were treated with the FlowTriever System and FlowTriever2 Catheter.

    Treatment: FlowTriever2 Catheter

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
FlowTriever Pulmonary Embolectomy Clinical Study - FlowTriever2
Record updated
8 October 2025